CALD Gene Therapy Granted Breakthrough Therapy Designation – Rare Disease Report
Rare Disease Report |
CALD Gene Therapy Granted Breakthrough Therapy Designation
Rare Disease Report Supported by positive data from an ongoing Phase 2/3 study, bluebird bio's Lenti-D has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with cerebral adrenoleukodystrophy (CALD), … |
